Reaction
Glare reporting signals
As of the last recalculation, Glare appears in 501 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 37.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 23 | 37.7 | 37.7 |
| Brimonidine Tartrate | 13 | 31.1 | 31.1 |
| Timolol Maleate | 6 | 25.5 | 25.5 |
| Timolol | 6 | 20.9 | 20.9 |
| Aflibercept | 15 | 20.6 | 20.6 |
| Lifitegrast | 7 | 18.0 | 18.0 |
| Bimatoprost | 9 | 13.2 | 13.2 |